Company intelligence / Profile preview

PolyPid Ltd.

Ownership: Public · PYPD
Employees: ~42
Development stage: Phase 3

Overview

Lead product D-PLEX100 is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. The company is also in preclinical stages testing OncoPLEX for the treatment of solid tumors, beginning with glioblastoma.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Drug delivery systemsControlled-release therapeutics
Industry: Biotech

Drug pipeline

3 assets

D-PLEX100

2 more assets in the full pipeline.

Request access →

Partnerships

ImmunoGenesis, Inc.

Financials

Market cap: $98.5M
Total revenue: $0
Enterprise value: $93.5M

Beyond the preview

Go deeper on PolyPid Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PolyPid Ltd..

Explore the full profile